FDA Approves Ramucirumab Injection in Combination with Erlotinib for NSCLC

The FDA approved ramucirumab injection in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 mutations.

Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news